Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor α together with naive dendritic cells elicits significant suppression of tumor growth without toxicity

Human Gene Therapy

Volumn 12, Issue 17, 2001, Pages 2035-2049

  Kianmanesh, Alireza ^a   Hackett, Neil R ^a   Lee, Jay M ^b   Kikuchi, Toshiaki ^a   Korst, Robert J ^a,b   Crystal, Ronald G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT DNA; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL ACTIVATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IN VITRO STUDY; KNOCKOUT MOUSE; LYMPHOCYTOTOXICITY; MALE; MOLECULE; MOUSE; NONHUMAN; T LYMPHOCYTE; TUMOR CELL LINE; TUMOR GROWTH; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; CELL DIVISION; CELL SURVIVAL; DENDRITIC CELLS; FEMALE; GENE THERAPY; GENETIC VECTORS; IMMUNOTHERAPY, ADOPTIVE; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

ADENOVIRIDAE; ALPHAVIRUS; ANIMALIA;

EID: 0035684074     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340152677395     Document Type: Article

References (67)

1. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
2. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver
3. Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II
4. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo
5. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors
6. A model using radiation and plasmid-mediated tumor necrosis factor-alpha gene therapy for treatment of glioblastomas
7. Efficient adenoviral transfer of NF-kappaB inhibitor sensitizes melanoma to tumor necrosis factor-mediated apoptosis
8. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons
9. Immunobiology of dendritic cells
10. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis
11. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer
12. Complete regression of established murine hepatocellular carcinoma by in vivo tumor necrosis factor alpha gene transfer
13. Estimation of liver tumor volume using different formulas - An experimental study in rats
14. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer
15. Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer
16. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis
17. Review article: Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy
18. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients
19. Activated dendritic cells from bone marrow cells of mice receiving cytokine-expressing tumor cells are associated with the enhanced survival of mice bearing syngeneic tumors
20. Tumor necrosis factor alpha-induced leukocyte adhesion in normal and tumor vessels: Effect of tumor type, transplantation site, and host strain
21. Retroviral vector-mediated transfer of the tumor necrosis factor alpha gene into human cancer cells restores an apoptotic cell death program and induces a bystander-killing effect
22. TNF-alpha gene polymorphism: Clinical and biological implications
23. Spatial and temporal control of gene therapy using ionizing radiation
24. Suppression of in vivo tumorigenicity of human lung cancer cells by retrovirus-mediated transfer of the human tumor necrosis factor-alpha cDNA
25. Modulation of gene expression after replication-deficient, recombinant adenovirus-mediated gene transfer by the product of a second adenovirus vector
26. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma
27. Use of soluble recombinant TNF receptor to improve detection of TNF secretion in cultures of tumor infiltrating lymphocytes
28. TNF alpha and the TNF receptor superfamily: Structure-function relationship(s)
29. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
30. Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells
31. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors
32. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor
33. Efficacy of TNF-alpha gene-transduced tumor cells in treatment of established in vivo tumor
34. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo
35. Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results
36. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma
37. Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha
38. Tumour therapy in mice using adenovirus vectors expressing human TNF-α
39. A p75 tumor necrosis factor receptor-specific mutant of murine tumor necrosis factor alpha expressed from an adenovirus vector induces an antitumor response with reduced toxicity
40. Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature
41. Tumor necrosis factor as an antineoplastic agent: Pitfalls and promises
42. Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha "super-repressor.
43. Functional activities of receptors for tumor necrosis factor-alpha on human vascular endothelial cells
44. Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo
45. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha)
46. A novel recombinant fusion toxin targeting HER-2/NEU-over-expressing cells and containing human tumor necrosis factor
47. Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo
48. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium
49. Evidence for the involvement of endothelial cell integrin alpha Vbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma
50. An apoptosis-inducing gene therapy for pancreatic cancer with a combination of 55-kDa tumor necrosis factor (TNF) receptor gene transfection and mutein TNF administration
51. Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor
52. Dendritic cells as adjuvants for immune-mediated resistance to tumors
53. Adenovirus-mediated wild-type-p53-gene expression sensitizes TNF-resistant tumor cells to TNF-induced cytotoxicity by altering the cellular redox state
54. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity
55. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study
56. The two different receptors for tumor necrosis factor mediate distinct cellular responses
57. Experimental and clinical studies of cytokine gene-modified tumor cells
58. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan
59. Tumor necrosis factor: A pleiotropic cytokine and therapeutic target
60. Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: A pharmacokinetic study in pigs
61. Human TNF mutants with selective activity on the p55 receptor
62. Gene transfer of human TNF alpha into glioblastoma cells permits modulation of M.D.r1 expression and potentiation of chemosensitivity
63. M.D.r1 promoter-driven tumor necrosis factor-alpha expression for a chemotherapy-controllable combined in vivo gene therapy and chemotherapy of tumors
64. Tumor necrosis factor-related ligands and receptors
65. Adenovirus-mediated TNF-alpha gene transfer induces significant tumor regression in mice
66. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer
67. Tumor necrosis factor